Dataset Information
A preliminary study of micro-RNAs as minimally invasive biomarkers for the diagnosis of prostate cancer patients.
Ontology highlight
ABSTRACT: Background
A prostate cancer diagnosis is based on biopsy sampling that is an invasive, expensive procedure, and doesn't accurately represent multifocal disease.Methods
To establish a model using plasma miRs to distinguish Prostate cancer patients from non-cancer controls, we enrolled 600 patients histologically diagnosed as having or not prostate cancer at biopsy. Two hundred ninety patients were eligible for the analysis. Samples were randomly divided into discovery and validation cohorts.Results
NGS-miR-expression profiling revealed a miRs signature able to distinguish prostate cancer from non-cancer plasma samples. Of 51 miRs selected in the discovery cohort, we successfully validated 5 miRs (4732-3p, 98-5p, let-7a-5p, 26b-5p, and 21-5p) deregulated in prostate cancer samples compared to controls (p???0.05). Multivariate and ROC analyses show miR-26b-5p as a strong predictor of PCa, with an AUC of 0.89 (CI?=?0.83-0.95;p?ConclusionsNoninvasive diagnostic tests may reduce the number of unnecessary prostate biopsies. The 2-miRs-diagnostic model (miR-26b-5p and miR-98-5p) and the 2-miRs-grade model (miR-26b-5p and miR-4732-3p) are promising minimally invasive tools in prostate cancer clinical management.
SUBMITTER: Giglio S
PROVIDER: S-EPMC7903618 | biostudies-literature | 2021 Feb
REPOSITORIES: biostudies-literature
Publications
A preliminary study of micro-RNAs as minimally invasive biomarkers for the diagnosis of prostate cancer patients.
Journal of experimental & clinical cancer research : CR 20210223 1
<h4>Background</h4>A prostate cancer diagnosis is based on biopsy sampling that is an invasive, expensive procedure, and doesn't accurately represent multifocal disease.<h4>Methods</h4>To establish a model using plasma miRs to distinguish Prostate cancer patients from non-cancer controls, we enrolled 600 patients histologically diagnosed as having or not prostate cancer at biopsy. Two hundred ninety patients were eligible for the analysis. Samples were randomly divided into discovery and validat ...[more]
